Denis Chem Lab Ltd

DENIS CHEM LAB LIMITED — Trading Window Closure from 1st October, 2026 until 48 hours after the declaration of Unaudited Financial Results for the quarter ended on 30th September, 2026

MD re-appointment

• Re-appointed as MD for three years from 1 Aug 2026 to 31 Jul 2029 due to continued responsibilities.
• Special Resolution approved by members at the 45th AGM via VC/OAVM on 25 Sep 2026.
• Profile: Dr. Himanshu C. Patel, B.E., M.S., Ph.D.; 70+ years in Medical and Pharmaceuticals.
• Related parties: Dr. Himanshu C. Patel related to Anar H. Patel and Dinesh B. Patel.
• Not debarred from holding office by SEBI or any authority.

MD Re-appointment

• MD Dr. Himanshu C. Patel re-appointed for a 3-year term from 1 Aug 2026 to 31 Jul 2029.
• Shareholders approved via Special Resolution at the AGM held on 25 Sep 2026.
• Term expired 31 Jul 2026; continued responsibilities warranted the reappointment.
• Profile: BE, MS, PhD with over seven decades in medical and pharma fields.
• Related parties: Dr. Himanshu C. Patel is related to Anar H. Patel and Dinesh B. Patel.
• Not debarred from office by SEBI or any authority.
• No other board or committee changes reported.

Secretarial Auditor Appointment

• Shareholders approved appointment of Kashyap R. Mehta & Partners as Secretarial Auditors for FY 2026-27 to FY 2030-31.
• Term is five consecutive years commencing from FY 2026-27.
• Auditors are Ahmedabad-based firm Kashyap R. Mehta & Partners.
• Disclosure: No relationships between auditors and the company.

AGM Details

• Date/time/mode: 25 Sep 2026, 12:00 IST, VC/OAVM.
• Remote e-voting: 22–24 Sep 2026; eligibility cut-off: 18 Sep 2026.
• Venue deemed at registered office; proceedings via VC/OAVM.
• Scrutinizer: Kashyap R. Mehta & Partners; report dated 25 Sep 2026.

Resolutions and outcomes

• Resolution 1: Adoption of audited financials and reports; Ordinary; Passed 99.31% in favour.
• Resolution 2: Dividend of Rs 2.50 per share; Ordinary; Passed 99.31%.
• Resolution 3: Re-appoint Anar Patel by rotation; Ordinary; Passed 99.30%.
• Resolution 4: Ratify cost auditor remuneration; Ordinary; Passed 99.31%.
• Resolution 5: Appoint Secretarial Auditors; Ordinary; Passed 99.31%.
• Resolution 6: MD re-appointment Aug 2026–Jul 2029; Special; Passed 99.31%.

Directors

• Anar Patel reappointed by rotation.
• Himanshu C. Patel re-appointed as MD for 3 years.

Auditors

• Cost Auditor remuneration ratified for FY2026-27.
• Secretarial Auditor appointed for five-year term (2026–31).

Related party transactions

• No material related party transactions approved.

AGM Details

• Date/time: 25 September 2026, 12:00 p.m. IST; mode: VC/OAVM.
• No physical venue; meeting conducted via video conference and OAVM.
• Remote e-voting window: 22–24 September 2026; e-voting during AGM.
• Meeting duration: 12:00–12:14 IST.

Key Resolutions

• Adopt audited financial statements and reports – Ordinary.
• Declare dividend of Rs 2.50 per equity share – Ordinary.
• Reappoint Anar Patel by rotation – Ordinary.
• Remuneration to Cost Auditors – Ordinary.
• Appoint Secretarial Auditors for five years – Ordinary.
• Re-appoint Dr. Himanshu Patel as MD for 3 years – Special.

Voting status

• E-voting results to be declared within 2 working days after AGM.

AGM Details

• 45th AGM scheduled for 25 September 2026 at 12:00 IST via VC/OAVM.

Ordinary Business

• Adopt Audited Financial Statements for year ended 31 March 2026.
• Declare final dividend per equity share for FY 2025-26.
• Re-appoint director retiring by rotation.

Special Business

• Cost Auditors remuneration and appointment for 2026-27.
• Secretarial Auditors appointment for five consecutive years (FY 2026-27 to 2030-31).
• Managing Director re-appointment for three-year term with board-approved remuneration.

Dividend

• Final dividend proposal for FY ended March 2026; per-share amount to be announced if approved.

Directors & MD Changes

• Managing Director re-appointment for three-year term from Aug 2026.
• Director retiring by rotation proposed for re-appointment.

Auditors

• Statutory Auditors: continuing without change.
• Cost Auditor to be appointed for FY 2026-27; remuneration as approved.

Related Party Transactions

• Related party transactions occurred in ordinary course; not material.
• Includes rent, procurements, and remuneration to related parties.

Other Material Approvals

• CSR activities and CSR policy; CSR expenditure disclosed; CSR committee functioning.

Financial highlights

• Revenue from operations: ₹4,399.67 lakh in Q1 FY27 (Standalone, unaudited).
• Total income: ₹4,444.67 lakh; YoY growth ~2%.
• Expenses: ₹4,180.30 lakh; materials ₹2,383.17; employee ₹419.35; depreciation ₹152.99.
• Profit before tax: ₹264.37 lakh; tax ₹59.85 lakh; PAT ₹204.52 lakh.
• EPS (basic/diluted): ₹1.47 for Q1 FY27.
• Single segment: transfusion solutions in bottles.
• PAT declined ~17% YoY to ₹204.52 lakh.